about
Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growthDose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunctionThioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions.Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.Development of molecularly targeted agents and immunotherapies in small cell lung cancer.Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.Alternative splicing in prostate cancerRB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate CancerGenomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair DeficiencyAndrogen receptor splice variant-7 expression emerges with castration resistance in prostate cancerImmunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancerIL-23 secreted by myeloid cells drives castration-resistant prostate cancerDocetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate CancersNuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the DetailInvestigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone SensitivitySingle-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisDissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate CancerClinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAndrogen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancerProstate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy MeetingActivation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer
P50
Q24321127-3ADFCCA5-118A-4FED-8332-40302A60730EQ33421995-1F5F798D-3A91-449C-8B3A-BE318C69F07BQ33494790-0970A32C-DC03-4D7E-9B9A-C749B109C083Q35845580-B50E101D-DD18-48C6-89CA-FA68BA7D69B8Q38731861-F0302C1B-6316-48E4-A74F-45274BE176E3Q38802811-9CCF944D-9E5A-4364-B64D-FFFF4647C2F8Q38815964-E039F428-DD84-4C04-9C4B-A9FDC0DF6DFBQ39819392-2CB374A4-6452-47AA-AB9B-88B97D7C0B51Q41832140-6A190BCB-8F1E-4F2F-9F98-5FD792E3BFFFQ42125180-32F36096-B648-47BE-9189-DBE8E8DE4A40Q49963122-7825B3EF-6ADF-45AF-B7ED-171B918DBC9CQ50230942-33974592-C20D-4848-886F-CA464D19738BQ50588643-1D52DE16-4518-457A-AE5C-B1CAE7CAD5C9Q52648064-5A90F2C7-F161-4772-A7CC-DE41E4330CB8Q53230423-0E4FFAED-FADC-4D6D-8F19-EC78F9054403Q57107634-059A4546-C2CE-45D7-BD43-FD4F6FC4B4EEQ57696178-A03DB2DB-32E1-4DF6-83A9-1B5F84358201Q57814257-85FA0F44-563F-46A4-858B-24C30BB58C4CQ58598144-DD425D21-9A49-441C-A1ED-C7F46618B05FQ58764307-3FA2490C-9F61-44F8-8180-C23B8B7CAC3FQ59066536-921E9EBE-30F4-48EA-9313-09D226B78B3FQ89133950-F5DCC7A2-778D-4803-A231-FD56D9A24AF7Q89337019-F93BEC93-2B1A-4B17-A3FF-F3F42EE9689DQ89357149-BB3DCB68-F4D0-4C0B-87AB-B31DFD21EF1BQ90697700-C29BC422-4999-42C5-9B88-514A0156FA54Q90858658-C4442394-6844-4B3D-BA27-68EA64AADEFDQ91551807-DCD2A006-4196-4EF3-9DC6-4EE621AB1082Q91621093-6A385B8F-E6D2-4165-B2BA-EEB5D936F08EQ91676732-1004F21D-8EA5-4CC9-B531-E4B08FF45396Q91875640-1C1E7BC1-F161-4697-9D05-DA93EEC1646FQ92884325-A8EF98BF-8CCC-48DE-A8A7-BE4FCB58CE51
P50
description
researcher (ORCID 0000-0002-3740-1612)
@en
name
Adam Sharp
@en
type
label
Adam Sharp
@en
prefLabel
Adam Sharp
@en
P31
P496
0000-0002-3740-1612